MiNK Therapeutics(INKT) - 2023 Q4 - Annual Results

EXHIBIT 99.1 MiNK Reports Fourth Quarter and Year-End 2023 Results NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune- mediated diseases, today announced results for the fourth quarter and full-year 2023. MiNK executives will host a conference call and webcast a ...